SCHEMBL22874752

SCHEMBL22874752

CC(C)C1CCN(C(=O)CCC(F)F)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.44
GNAI3 P08754 7/20 0.41
GNAO1 P09471 7/20 0.41
GNAI1 P63096 7/20 0.41
CACNA1B Q00975 2/20 0.40
DPP4 P27487 2/20 0.39
DPP8 Q6V1X1 1/20 0.39
DPP9 Q86TI2 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
USP2 O75604 1/20 0.38
LMNA P02545 1/20 0.38
CYP3A4 P08684 1/20 0.38
HPGD P15428 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22874723 0.88 NPC1 (0.46) NPC1GNAI3GNAO1GNAI1CACNA1B
SCHEMBL7919921 0.84 NPC1 (0.48) NPC1GNAI3GNAO1GNAI1MEN1
SCHEMBL22875166 0.83 NPC1 (0.44) NPC1GNAI3GNAO1GNAI1CACNA1B
SCHEMBL14147220 0.82 NPC1 (0.47) NPC1GNAI3GNAO1GNAI1MEN1
SCHEMBL22874744 0.82 POLB (0.42) NPC1GNAI3GNAO1GNAI1CACNA1B
SCHEMBL19645417 0.81 GNAI3 (0.49) NPC1GNAI3GNAO1GNAI1CACNA1B
SCHEMBL23551094 0.81 NPC1 (0.46) NPC1GNAI3GNAO1GNAI1ALDH1A1
SCHEMBL18232472 0.81 NPC1 (0.46) NPC1GNAI3GNAO1GNAI1ALDH1A1
SCHEMBL22874721 0.81 GNAI3 (0.57) NPC1GNAI3GNAO1GNAI1MEN1
SCHEMBL25075495 0.80 NPC1 (0.42) NPC1GNAI3GNAO1GNAI1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11753397-B2 Cereblon binders for the degradation of ikaros C4 THERAPEUTICS, INC. (US) 2023-09-12 US disclosed
US-11753397-B2 Cereblon binders for the degradation of ikaros C4 THERAPEUTICS, INC. (US) 2023-09-12 US disclosed
US-20210009559-A1 CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS C4 THERAPEUTICS, INC. (US) 2021-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11753397-B2 Cereblon binders for the degradation of ikaros CRBN, IKZF1, IKZF3 NPC1 2155/4885GNAI3 1551/4885GNAO1 1521/4885
US-20210009559-A1 CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS CRBN, IKZF1, IKZF3 NPC1 2645/4885GNAI3 2181/4885GNAO1 1777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.